All In Biotech

Free tool

FAERS Monitor: Besremi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761166 or its brand name (Besremi, Ropeginterferon Alfa-2b-Njft). Reports on generic versions are filed under their own applications.

Reports

1,859

Serious

429

23% of reports

Hospitalization

180

Death reported

31

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue355
  • off label use304
  • pruritus177
  • headache157
  • product dose omission issue118
  • influenza like illness111
  • nausea110
  • inappropriate schedule of product administration107
  • diarrhoea104
  • pain104
  • arthralgia101
  • haematocrit increased93
  • platelet count increased91
  • dizziness84
  • incorrect dose administered77

Reports by year received

View as table
YearReports
20173
20201
20211
2022382
2023774
2024217
2025189
2026292

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,300 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haematocrit increasedSignal93481.3393.142,307
platelet count increasedSignal9179.565.06,934
influenza like illnessSignal11115.312.81,471
inappropriate schedule of product administrationSignal1076.75.6519
pruritusSignal1775.24.5609
fatigueSignal3555.24.71,232
product dose omission issueSignal1184.53.8327
off label useSignal3043.93.5689
incorrect dose administeredSignal773.83.1159
headacheSignal1572.82.4190
arthralgiaSignal1012.72.3113
pain1041.91.646
dizziness841.91.536
diarrhoea1041.81.539
nausea1101.61.323

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.